{"pmid":32344449,"title":"Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness.","text":["Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness.","Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2( (SARS-CoV-2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC50 ) and to help guide researchers in dose-selection for COVID-19 prophylactic studies. To maintain weekly troughs above EC50 in >50% of subjects at steady state in a pre-exposure prophylaxis setting, an 800 mg loading dose followed by 400 mg twice or three times weekly is required. In an exposure driven post-exposure prophylaxis setting, 800 mg loading dose followed in 6 hours by 600 mg, then 600 mg daily for 4 more days achieved daily troughs above EC50 in >50% subjects. These doses are higher than recommended for malaria chemoprophylaxis, and clinical trials are needed to establish safety and efficacy.","Clin Pharmacol Ther","Al-Kofahi, Mahmoud","Jacobson, Pamala","Boulware, David R","Matas, Arthur","Kandaswamy, Raja","Jaber, Mutaz M","Rajasingham, Radha","Young, Jo-Anne H","Nicol, Melanie R","32344449"],"abstract":["Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2( (SARS-CoV-2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC50 ) and to help guide researchers in dose-selection for COVID-19 prophylactic studies. To maintain weekly troughs above EC50 in >50% of subjects at steady state in a pre-exposure prophylaxis setting, an 800 mg loading dose followed by 400 mg twice or three times weekly is required. In an exposure driven post-exposure prophylaxis setting, 800 mg loading dose followed in 6 hours by 600 mg, then 600 mg daily for 4 more days achieved daily troughs above EC50 in >50% subjects. These doses are higher than recommended for malaria chemoprophylaxis, and clinical trials are needed to establish safety and efficacy."],"journal":"Clin Pharmacol Ther","authors":["Al-Kofahi, Mahmoud","Jacobson, Pamala","Boulware, David R","Matas, Arthur","Kandaswamy, Raja","Jaber, Mutaz M","Rajasingham, Radha","Young, Jo-Anne H","Nicol, Melanie R"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344449","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1874","keywords":["covid-19","sars-cov-2","hydroxychloroquine","pharmacokinetics"],"topics":["Treatment"],"weight":1,"_version_":1665351883917623296,"score":8.574329,"similar":[{"pmid":32150618,"pmcid":"PMC7108130","title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","text":["In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50=0.72 muM) was found to be more potent than chloroquine (EC50=5.47 muM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.","Clin Infect Dis","Yao, Xueting","Ye, Fei","Zhang, Miao","Cui, Cheng","Huang, Baoying","Niu, Peihua","Liu, Xu","Zhao, Li","Dong, Erdan","Song, Chunli","Zhan, Siyan","Lu, Roujian","Li, Haiyan","Tan, Wenjie","Liu, Dongyang","32150618"],"abstract":["BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50=0.72 muM) was found to be more potent than chloroquine (EC50=5.47 muM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro."],"journal":"Clin Infect Dis","authors":["Yao, Xueting","Ye, Fei","Zhang, Miao","Cui, Cheng","Huang, Baoying","Niu, Peihua","Liu, Xu","Zhao, Li","Dong, Erdan","Song, Chunli","Zhan, Siyan","Lu, Roujian","Li, Haiyan","Tan, Wenjie","Liu, Dongyang"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32150618","week":"202011|Mar 09 - Mar 15","doi":"10.1093/cid/ciaa237","keywords":["chloroquine","hydroxychloroquine","sars-cov-2"],"link_comment_in":"32241791","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","PBPK","PBPK"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Chloroquine","Hydroxychloroquine","chloroquine diphosphate"],"_version_":1664640874859986944,"score":608.11487},{"pmid":32285930,"title":"Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.","text":["Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.","Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus Disease of 2019 (COVID-19) treatment. The optimal dosing of HCQ is unknown. Our goal was to integrate historic and emerging pharmacological and toxicity data to understand safe and efficacious HCQ dosing strategies for COVID-19 treatment. The data sources included were 1) longitudinal clinical, pharmacokinetic, and virologic data from patients with severe acute respiratory syndrome-2 (SARS-CoV-2) infection who received HCQ with or without azithromycin (n=116), 2) in vitro viral replication data and SARS-CoV-2 viral load inhibition by HCQ, 3) a population pharmacokinetic model of HCQ and 4) a model relating chloroquine pharmacokinetics to QTc prolongation. A mechanistic PK/virologic/QTc model for HCQ was developed and externally validated to predict SARS-CoV-2 rate of viral decline and QTc prolongation. SARS-CoV-2 viral decline was associated with HCQ pharmacokinetics (p<0.001). The extrapolated patient EC50 was 4.7 microM, comparable to the reported in vitro EC50 's. HCQ doses > 400 mg BID for >/=5 days were predicted to rapidly decrease viral loads, reduce the proportion of patients with detectable SARS-CoV-2 infection, and shorten treatment courses, compared to lower dose (</=400 mg daily) regimens. However, HCQ doses >600 mg BID were also predicted to prolong QTc intervals. This prolongation may have clinical implications warranting further safety assessment. Due to COVID-19's variable natural history, lower dose HCQ regimens may be indistinguishable from controls. Evaluation of higher HCQ doses is needed to ensure adequate safety and efficacy.","Clin Pharmacol Ther","Garcia-Cremades, Maria","Solans, Belen P","Hughes, Emma","Ernest, Jacqueline P","Wallender, Erika","Aweeka, Francesca","Luetkemeyer, Annie","Savic, Radojka M","32285930"],"abstract":["Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus Disease of 2019 (COVID-19) treatment. The optimal dosing of HCQ is unknown. Our goal was to integrate historic and emerging pharmacological and toxicity data to understand safe and efficacious HCQ dosing strategies for COVID-19 treatment. The data sources included were 1) longitudinal clinical, pharmacokinetic, and virologic data from patients with severe acute respiratory syndrome-2 (SARS-CoV-2) infection who received HCQ with or without azithromycin (n=116), 2) in vitro viral replication data and SARS-CoV-2 viral load inhibition by HCQ, 3) a population pharmacokinetic model of HCQ and 4) a model relating chloroquine pharmacokinetics to QTc prolongation. A mechanistic PK/virologic/QTc model for HCQ was developed and externally validated to predict SARS-CoV-2 rate of viral decline and QTc prolongation. SARS-CoV-2 viral decline was associated with HCQ pharmacokinetics (p<0.001). The extrapolated patient EC50 was 4.7 microM, comparable to the reported in vitro EC50 's. HCQ doses > 400 mg BID for >/=5 days were predicted to rapidly decrease viral loads, reduce the proportion of patients with detectable SARS-CoV-2 infection, and shorten treatment courses, compared to lower dose (</=400 mg daily) regimens. However, HCQ doses >600 mg BID were also predicted to prolong QTc intervals. This prolongation may have clinical implications warranting further safety assessment. Due to COVID-19's variable natural history, lower dose HCQ regimens may be indistinguishable from controls. Evaluation of higher HCQ doses is needed to ensure adequate safety and efficacy."],"journal":"Clin Pharmacol Ther","authors":["Garcia-Cremades, Maria","Solans, Belen P","Hughes, Emma","Ernest, Jacqueline P","Wallender, Erika","Aweeka, Francesca","Luetkemeyer, Annie","Savic, Radojka M"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32285930","week":"202016|Apr 13 - Apr 19","doi":"10.1002/cpt.1856","keywords":["infectious disease","pharmacokinetics-pharmacodynamics","pharmacometrics","translational pharmacokinetics-pharmacodynamics","viral dynamics"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Azithromycin","Hydroxychloroquine","Chloroquine"],"_version_":1664636391622967296,"score":561.8238},{"pmid":32292817,"pmcid":"PMC7128742","title":"Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.","text":["Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.","Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at does matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6mg/kg/day 1 (loading dose) followed by 5mg/kg/day, with a maximum limit of 600mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.","One Health","Picot, Stephane","Marty, Aileen","Bienvenu, Anne-Lise","Blumberg, Lucille H","Dupouy-Camet, Jean","Carnevale, Pierre","Kano, Shigeyuki","Jones, Malcolm K","Daniel-Ribeiro, Claudio Tadeu","Mas-Coma, Santiago","32292817"],"abstract":["Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at does matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6mg/kg/day 1 (loading dose) followed by 5mg/kg/day, with a maximum limit of 600mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people."],"journal":"One Health","authors":["Picot, Stephane","Marty, Aileen","Bienvenu, Anne-Lise","Blumberg, Lucille H","Dupouy-Camet, Jean","Carnevale, Pierre","Kano, Shigeyuki","Jones, Malcolm K","Daniel-Ribeiro, Claudio Tadeu","Mas-Coma, Santiago"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292817","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.onehlt.2020.100131","keywords":["covid19","chloroquine","hydroxychloroquine","immunomodulation","sars-cov2","systemic lupus erythematosus"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Hydroxychloroquine"],"_version_":1664636192768917505,"score":437.6315},{"pmid":32320477,"title":"Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation.","text":["Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation.","As chloroquine (CHQ) is part of the Dutch Centre for Infectious Disease Control COVID-19 experimental treatment guideline, pediatric dosing guidelines are needed. Recent pediatric data suggest that existing WHO dosing guidelines for children with malaria are suboptimal. The aim of our study was to establish best-evidence to inform pediatric CHQ doses for children infected with COVID-19. A previously developed physiologically-based pharmacokinetic (PBPK) model for CHQ was used to simulate exposure in adults and children and verified against published pharmacokinetic data. The COVID-19 recommended adult dosage regimen of 44mg/kg total was tested in adults and children to evaluate the extent of variation in exposure. Based on differences in AUC0-70h the optimal CHQ dose was determined in children of different ages compared to adults. Revised doses were re-introduced into the model to verify that overall CHQ exposure in each age band was within 5% of the predicted adult value. Simulations showed differences in drug exposure in children of different ages and adults when the same body-weight based dose is given. As such, we propose the following total cumulative doses: 35 mg/kg (CHQ base) for children 0-1 month, 47 mg/kg for 1-6 months, 55 mg/kg for 6 months-12 years and 44 mg/kg for adolescents and adults, not to exceed 3300 mg in any patient. Our study supports age-adjusted CHQ dosing in children with COVID-19 in order to avoid suboptimal or toxic doses. The knowledge-driven, model-informed dose selection paradigm can serve as a science-based alternative to recommend pediatric dosing when pediatric clinical trial data is absent.","Clin Pharmacol Ther","Verscheijden, Laurens F M","van der Zanden, Tjitske M","van Bussel, Lianne P M","de Hoop-Sommen, Marika","Russel, Frans G M","Johnson, Trevor N","de Wildt, Saskia N","32320477"],"abstract":["As chloroquine (CHQ) is part of the Dutch Centre for Infectious Disease Control COVID-19 experimental treatment guideline, pediatric dosing guidelines are needed. Recent pediatric data suggest that existing WHO dosing guidelines for children with malaria are suboptimal. The aim of our study was to establish best-evidence to inform pediatric CHQ doses for children infected with COVID-19. A previously developed physiologically-based pharmacokinetic (PBPK) model for CHQ was used to simulate exposure in adults and children and verified against published pharmacokinetic data. The COVID-19 recommended adult dosage regimen of 44mg/kg total was tested in adults and children to evaluate the extent of variation in exposure. Based on differences in AUC0-70h the optimal CHQ dose was determined in children of different ages compared to adults. Revised doses were re-introduced into the model to verify that overall CHQ exposure in each age band was within 5% of the predicted adult value. Simulations showed differences in drug exposure in children of different ages and adults when the same body-weight based dose is given. As such, we propose the following total cumulative doses: 35 mg/kg (CHQ base) for children 0-1 month, 47 mg/kg for 1-6 months, 55 mg/kg for 6 months-12 years and 44 mg/kg for adolescents and adults, not to exceed 3300 mg in any patient. Our study supports age-adjusted CHQ dosing in children with COVID-19 in order to avoid suboptimal or toxic doses. The knowledge-driven, model-informed dose selection paradigm can serve as a science-based alternative to recommend pediatric dosing when pediatric clinical trial data is absent."],"journal":"Clin Pharmacol Ther","authors":["Verscheijden, Laurens F M","van der Zanden, Tjitske M","van Bussel, Lianne P M","de Hoop-Sommen, Marika","Russel, Frans G M","Johnson, Trevor N","de Wildt, Saskia N"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320477","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cpt.1864","keywords":["children","chloroquine","dose recommendation","pediatrics","physiologically-based pharmacokinetics modelling"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087892824064,"score":377.00455},{"pmid":32281213,"title":"A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).","text":["A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).","OBJECTIVE: The pandemic Coronavirus Disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID-19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID-19. METHODS: PubMed, EMBASE, ClinicalTrials.gov, ICTRP, and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies) until 30 March 2020. The available literature was critically appraised. RESULTS: A total of 45 articles were screened and five (three in vitro pre-clinical studies and two clinical opinions) were included. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID-19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available. CONCLUSION: Although pre-clinical results are promising, till date, there is dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID-19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID-19 needs to be thoroughly evaluated in observational studies or high quality randomized controlled studies.","Int J Rheum Dis","Shah, Sanket","Das, Saibal","Jain, Avinash","Misra, Durga Prasanna","Negi, Vir Singh","32281213"],"abstract":["OBJECTIVE: The pandemic Coronavirus Disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID-19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID-19. METHODS: PubMed, EMBASE, ClinicalTrials.gov, ICTRP, and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies) until 30 March 2020. The available literature was critically appraised. RESULTS: A total of 45 articles were screened and five (three in vitro pre-clinical studies and two clinical opinions) were included. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID-19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available. CONCLUSION: Although pre-clinical results are promising, till date, there is dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID-19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID-19 needs to be thoroughly evaluated in observational studies or high quality randomized controlled studies."],"journal":"Int J Rheum Dis","authors":["Shah, Sanket","Das, Saibal","Jain, Avinash","Misra, Durga Prasanna","Negi, Vir Singh"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281213","week":"202016|Apr 13 - Apr 19","doi":"10.1111/1756-185X.13842","keywords":["covid-19","prevention","sars-cov-2","chloroquine","high-risk","hydroxychloroquine"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Chloroquine","Hydroxychloroquine"],"_version_":1664636703967543296,"score":349.38843}]}